News | January 27, 2015

Ortho-Clinical Diagnostics Introduces Test to Assess Risk for Acute Kidney Injury

Early knowledge of AKI risk may prompt closer patient monitoring and help prevent permanent kidney damage or death

Nephrocheck Test System, Blood testing, contrast media

Image courtesy of Astute Medical

January 27, 2015 — Ortho-Clinical Diagnostics Inc. announced the nationwide availability to hospitals of the Nephrocheck Test System designed to help healthcare providers identify patients at risk of developing moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment.

In comparing patients with AKI to patients without AKI, hospital and the intensive care unit lengths of stay double, as do costs of care and readmission rates.  Death rates at one year are higher among patients with AKI alone, compared to those patients with heart attack alone.

AKI usually lacks signs and symptoms and can potentially result in irreversible kidney damage if recognition is delayed. In clinical studies, the Nephrocheck Test identified the majority of patients that developed moderate to severe AKI within 12 hours of assessment.

The Nephrocheck Test result, called the AKIRisk Score, has the ability to distinguish patients with AKI from those without AKI. Based on results from clinical studies, patients with a positive AKIRisk Score (greater than the cutoff of 0.3) have a one in four to a one in three chance of developing moderate or severe AKI within 12 hours of assessment.

To calculate the AKIRisk Score, the Nephrocheck Test System measures the concentrations of two urinary biomarkers using the Astute140 Meter. The two novel biomarkers -- tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7, are thought to be involved in G1 cell cycle arrest in the earliest phases of injury.

In July 2014, Ortho-Clinical Diagnostics entered into collaboration with Astute Medical Inc., the developer of the Nephrocheck Test System, to become the exclusive sales agent for Astute Medical’s Nephrocheck Test and the Astute140 Meter in the United States and in certain countries of the European Union.

For more information: www.orthoclinical.com/en-us/Pages/Home.aspx, www.astutemedical.com

 

 

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...